Journals / Turkish Journal of Urology / 2020 / Cilt: 46 - Sayı: 3

Turkish Urologists’ preferences regarding antibiotic prophylaxis for transrectal prostate biopsy

Pages
213–218
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The most common antibiotic agent preferred for prophylaxis was ciprofloxacin (65%).Conclusion: The biopsy behavior of Turkish urologists was mostly compatible with the literature, but it was revealed that Turkish urologists do not prefer single-dose antibiotic therapy, and their practice patterns regarding the administration of pre-biopsy rectal swabbing are inconsistent with the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Antibiotic prophylaxis for transrectal prostate biopsy (PB) is very important in preventing infectious complications, and in this study, we aimed to evaluate the antibiotic preferences of Turkish urologist for transrectal PB.Material and methods: The survey about PB and antibiotic prophylaxis behaviors was administered to urologists working in Turkey who had previously participated in at least one international and one national congress.Results: A total of 237 urologists were included in the study.
📊
Key Findings & Data:Antibiotic prophylaxis prior to PB was performed by 234 (98.7%) participants.
💡
Conclusion & Impact:The most common antibiotic agent preferred for prophylaxis was ciprofloxacin (65%).Conclusion: The biopsy behavior of Turkish urologists was mostly compatible with the literature, but it was revealed that Turkish urologists do not prefer single-dose antibiotic therapy, and their practice patterns regarding the administration of pre-biopsy rectal swabbing are inconsistent with the literature.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Antibiotic prophylaxis for transrectal prostate biopsy (PB) is very important in preventing infectious complications, and in this study, we aimed to evaluate the antibiotic preferences of Turkish urologist for transrectal PB.Material and methods: The survey about PB and antibiotic prophylaxis behaviors was administered to urologists working in Turkey who had previously participated in at least one international and one national congress.Results: A total of 237 urologists were included in the study. Antibiotic prophylaxis prior to PB was performed by 234 (98.7%) participants. Rectal swabbing prior to PB was not performed by 227 (95.8%) participants. The most common complication associated with PB was prostatitis (63%), followed by urinary tract infection (29%). Only 25.7% of Turkish urologists reported a single dose of antibiotic prophylaxis. Our participants often administered antibiotic prophylaxis for a period of 3, 5, or 7 days (16%, 21.1%, 35.9%, respectively). The most common antibiotic agent preferred for prophylaxis was ciprofloxacin (65%).Conclusion: The biopsy behavior of Turkish urologists was mostly compatible with the literature, but it was revealed that Turkish urologists do not prefer single-dose antibiotic therapy, and their practice patterns regarding the administration of pre-biopsy rectal swabbing are inconsistent with the literature.

🔖

Cite This Article

DEMİRTAŞ, A., EREN, E., SÖNMEZ, G., TOMBUL, Ş. T., ALP, E., BİOPSY, T. U. A. S. G. O. P. (2020). Turkish Urologists’ preferences regarding antibiotic prophylaxis for transrectal prostate biopsy. Turkish Journal of Urology, Cilt: 46 - Sayı: 3, 213–218. https://ajindex.com/articles/379591

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010. [CrossRef] 2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. [CrossRef] 3. Roberts MJ, Scott S, Harris PN, Naber K, Wagenlehner FME, Doi SAR. Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World J Urol 2018;36:323-30. [CrossRef] 4. Lundström KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, et al. Nationwide population-based study of infections after transrectal ultrasound guided prostate biopsy. J Urol 2014;192:1116-22. [CrossRef] 5. Bruyere F, Malavaud S, Bertrand P, Decock A, Cariou G, Doublet JD, et al. Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy. J Urol 2015;193:145-50. [CrossRef] 6. Wagenlehner FME, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 2013;63:521-7. [CrossRef] 7. Cuevas O, Oteo J, Lázaro E, Aracil B, de Abajo F, García-Cobos S, et al. Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/ clavulanic acid. J Antimicrob Chemother 2011;66:664-9. [CrossRef] 8. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-4. [CrossRef] 9. Smyth LG, Mulvin DW. Antibiotic prophylaxis for transrectal ultrasound biopsy of the prostate in Ireland. Ir J Med Sci 2012;181:33-5. [CrossRef] 10. Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk NT, et al. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother 2015;70:2068-73. [CrossRef] 11. Kalkanlı A, Gezmiş CT, Özkan A, Çilesiz NC, Yanaral F, Aydın M, et al. Comparison of Single and Prolonged Fluoroquinolone Prophylaxis and Risk Factors for Infectious Complications After Transrectal Prostate Biopsy. Balkan Med J 2018;35:373-7. [CrossRef